FDG-PET/CT in predicting aggressiveness of rectal cancer

Egyptian Journal of Radiology and Nuclear Medicine

Table 3 Correlations between metabolic parameters of FDG-PET/CT and patient/tumor characteristics

Variables	N	SUVmax*	p	SUV mean*	p	MTV*	P	TLG*	p
Size	33		0.85		0.25		0.003		0.003
Location			0.33		0.37		0.89		0.59
Lower^*	19	12.96 [6.6–22.3]		7.4 [3.88–13.88]		21.5 [10.94–25.4]		188.11[57.2–42.05]
Middle, lower^*	3	15.4 [7.36–17.8]		9.18 [4.3–10.62]		22.18 [16.02–40.72]		168.99 [84.1–421.2]
middle^*	7	20.6 [14.9–0]		12.9 [9.4–0]		18.56 [4.86–0]		173.53 [62.69–0]
Upper^*	4	20.99 [12.41–29.43]		10.78 [7.7–16.6]		23.87 [15.2–37.8]		322.4 [122.7–472.9]
Clinical stage			0.89		0.9		0.13		0.34
II^*	10	19.445 [10.92–35.8]		11.68 [6.1675–21.4]		18.785 [10.27–28.225]		229.58 [53.5–467.2]
IIIA^*	6	16.98 [9.32–25.45		10.4 [5.7325–15.315]		18.4 [11.97–25.09]		114.74 [71.42–387.3]
IV^*	17	17.5 [13.93–27.1]		9.97 [8.17–14.875]		25.42 [19.07–46.435]		315.58[150.7–507.8]
Metastasis load			0.78		0.9		0.104		0.18
Negative^*	16	19.25 [11.07–28.525]		11.68 [6.66–17.507]		18.4 [11.24–24.88]		170.45 [61.44–410.97]
Oligo–metastasis^*	6	17.87 [11.1–21.7]		10.61 [6.4–13.4]		23.33 [15.7–39.9]		208.48 [109.1–298.04]
multiple^*	11	17.3 [14.9–29.4]		9.8 [8.9–15.2]		33.34 [18.56–55.23]		362.8[173.5–550.6]